Roche aquires remyelination play Inception 5

Roche (SIX:ROG; OTCQX:RHHBY) is exercising its option to acquire Versant Venture’s remyelination play Inception 5 Inc. (San Diego, Calif.). Concurrently, the VC is doubling down on regenerative therapies for neurology through the launch of successor company Pipeline Therapeutics Inc., which has ambitions

Read the full 420 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE